Characteristics of Ongoing Clinical Trials of Psychogenic Substances for Psychiatric Disorders.
Journal of Clinical Psychopharmacology John L. Havlik, Sayana Isaac, Pralahad Raman et al.
As of late 2024, 181 ongoing clinical trials of psychogenic substances for psychiatric disorders are registered on ClinicalTrials.gov. Most are in phase 2 (51.4%) or phase 1 (18.2%), with psilocybin (35.4%) and ketamine (33.7%) the most studied compounds. Trials concentrate at a few leading academic institutions. Over 81% list their funding source as "other," and 86% of those are sponsored by universities or university-affiliated institutions. Blinding is not reported in 38.7% of trials. Major depressive disorder (51.9%), posttraumatic stress disorder (21.0%), and alcohol use disorder (11.6%) are the primary conditions targeted. The lack of clear funding disclosure indicates a need for greater transparency.